SERB Pays $800m For Boston Scientific Specialty Pharma Business

Device Maker Acquired The Drugs In $4.2bn BTG Buy Last Year

 
• By Reed Miller

The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.

Group of paper plane in one direction and with one individual pointing in the different way
Boston Scientific's sale of BTG Specialty Pharmaceuticals was anticipated when it bought BTG plc for $4.2bn • Source: Shutterstock

More from Deals

More from Business